admin – Page 7883 – Get News Story

Low Grade Glioma Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutic, Beigene

“Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the 7MM.

DelveInsight’s “Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast

Some of the key facts of the Low Grade Glioma Market Report:

The Low Grade Glioma market size was valued approximately USD 1 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
The anticipated introduction of prospective treatments such as Day One Biopharmaceuticals’ (DAY101), AnHeart Therapeutic’s (AB218), SpringWorks Therapeutics’ (mirdametinib), Servier’s (vorasidenib [AG- 881]), and additional therapies is likely to contribute to the potential expansion of the market size in the upcoming years.
In June 2022, Day One Biopharmaceuticals disclosed encouraging initial findings from its pivotal Phase II trial (FIREFLY-1) assessing tovorafenib (DAY101) in pediatric patients experiencing recurrence of low-grade glioma (pLGG).
As per the GLOBOCAN 2020 estimates, there were 308,102 newly reported cases of brain and central nervous system tumors worldwide in 2020, showing a higher incidence rate in developed nations.
In 2022, the collective new cases of Low-grade Gliomas (LGG) across the 7MM totaled around 9,000 and are expected to rise in the forecasted period.
In 2022, the United States reported a nearly 4,000-strong incident population of Low-grade Gliomas (LGG), representing roughly 40% of the total incident population across the 7MM.
In 2022, among the EU4 nations and the UK, Germany exhibited the highest diagnosed prevalence of Low-grade Gliomas (LGG), followed by France. Spain, on the other hand, reported the lowest number of cases within this category.
Key Low Grade Glioma Companies: Day One Biopharmaceuticals, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
Key Low Grade Glioma Therapies: Tovorafenib (DAY101), Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
The Low Grade Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.

Low Grade Glioma Overview

Low-grade Gliomas (LGG) constitute a diverse category of primary brain tumors commonly found in younger, otherwise healthy individuals. Typically, these tumors exhibit a relatively slow progression and extended survival rates compared to high-grade gliomas.

Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/low-grade-glioma-market

Low Grade Glioma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Low Grade Glioma Epidemiology Segmentation:

The Low Grade Glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Low Grade Glioma
Prevalent Cases of Low Grade Glioma by severity
Gender-specific Prevalence of Low Grade Glioma
Diagnosed Cases of Episodic and Chronic Low Grade Glioma

Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast

Low Grade Glioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Low Grade Glioma Therapies and Key Companies

Tovorafenib (DAY101): Day One Biopharmaceuticals
Vorasidenib: Servier
Mirdametinib: SpringWorks Therapeutics
AB-218: AnHeart Therapeutics
BGB-290: Beigene
Infigratinib: Helsinn
FT-2102 (Olutasidenib): Forma Therapeutics
Vinblastine + Bevacizumab: Hoffmann-La Roche, and others

Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape

Low Grade Glioma Market Strengths

Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Low Grade Glioma Market Opportunities

Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.

Scope of the Low Grade Glioma Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Low Grade Glioma Companies: Day One Biopharmaceuticals, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
Key Low Grade Glioma Therapies: Tovorafenib (DAY101), Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Low Grade Glioma Unmet Needs, KOL’s views, Analyst’s views, Low Grade Glioma Market Access and Reimbursement

To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Low Grade Glioma Market Report Introduction

2. Executive Summary for Low Grade Glioma

3. SWOT analysis of Low Grade Glioma

4. Low Grade Glioma Patient Share (%) Overview at a Glance

5. Low Grade Glioma Market Overview at a Glance

6. Low Grade Glioma Disease Background and Overview

7. Low Grade Glioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Low Grade Glioma

9. Low Grade Glioma Current Treatment and Medical Practices

10. Low Grade Glioma Unmet Needs

11. Low Grade Glioma Emerging Therapies

12. Low Grade Glioma Market Outlook

13. Country-Wise Low Grade Glioma Market Analysis (2019–2032)

14. Low Grade Glioma Market Access and Reimbursement of Therapies

15. Low Grade Glioma Market Drivers

16. Low Grade Glioma Market Barriers

17. Low Grade Glioma Appendix

18. Low Grade Glioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Low Grade Glioma Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutic, Beigene

EASI, the Dark Horse of the Smart Home Industry, Introduces Neom Futuristic City to Transform Middle East Industry

Neom represents a novel concept, a city of the future characterized by technology, green energy, and sustainability.

The Kingdom of Saudi Arabia, a nation that consistently brings forth surprises, in July 2022, witnessed the unveiling of an avant-garde urban design initiative by the Crown Prince known as “The Line.” This design concept emanates from Neom, a project introduced in Saudi Arabia’s “Vision 2030” plan in 2016. Neom is envisioned as a futuristic city imbued with technology, and the project’s overall budget reaches a staggering $500 billion.

Neom represents a novel concept, a city of the future characterized by technology, green energy, and sustainability. Its design philosophy seeks to seamlessly integrate human life with the natural environment, addressing contemporary urban challenges such as environmental and energy issues through innovative technological solutions.

As this vision of the future city advances, a company named EASI is emerging with unique charm and ambition on this beautiful landscape. EASI, perhaps not widely familiar to ordinary consumers, is, however, a rising star in the realm of smart homes.

At the core of EASI’s philosophy is a harmonious blend of technology, safety, and convenience, seamlessly integrated into eco-friendly and aesthetically pleasing designs. By prioritizing user experience and environmental sustainability, EASI sets new standards in home automation, promising not just a product, but a transformative lifestyle change.

EASI is dedicated to customizing smart home solutions and designing interiors, boasting an independent system for product development, sales, and services. The company aims to provide a global user base with a living environment that combines intelligence, safety, and convenience while embracing green energy and sustainability. The CEO of EASI hails from Dubai, and the company has five shareholders from Saudi Arabia, Europe, and the United Kingdom, fostering a cross-cultural collaboration that endows EASI with distinctive advantages in the international market.

EASI has invested substantial efforts and funds in product development and market testing. Their smart home products not only pursue innovation in functionality but also strive for a fusion of culture and fashion in design. For instance, all the fabric materials used in their soft furnishings can be customized with exclusive patterns based on the customer’s style and preferences. These fabrics are not only moisture-wicking and quick-drying but also possess inherent flame resistance, antimicrobial, and mold-resistant properties, as well as being antistatic and easy to clean. This design approach ensures both the practicality of the products and reflects EASI’s pursuit of a high-quality lifestyle, demonstrating environmental consciousness.

Furthermore, all smart home appliances in EASI’s whole-house customization can be scheduled via user terminal devices or through voice commands to an intelligent housekeeper. This level of automation significantly enhances user convenience, setting EASI apart in the field of smart homes.

Internally, EASI not only has a team of young designers entirely its own but also collaborates with renowned international design teams. Their comprehensive smart soft furnishing design, with a blend of history, culture, simplicity, fashion, and intelligent convenience, rapidly captures the attention of numerous consumers. The company has also devised a comprehensive global promotion strategy spanning multiple continents. Actively participating in international exhibitions, organizing influential product launch events, salons, and other means, EASI has established mutually beneficial promotional partnerships, conducting extensive market testing and salon promotions worldwide. It is reported that EASI has signed cooperation agreements with partners from various countries and regions worldwide, laying a solid foundation for the international development of its products.

As EASI continues to carve its niche in the smart home industry, its journey is more than just about technological advancement; it’s about shaping a future where technology, sustainability, and human-centric design converge. With its visionary approach, EASI is not just a company; it’s a harbinger of change in the way we perceive and interact with our living spaces. As it strides forward, EASI remains committed to its core values of innovation, customer satisfaction, and environmental responsibility, promising to redefine the essence of home living for generations to come.

Media Contact
Company Name: Easi Group Ltd
Contact Person: Abdelaziz
Email: Send Email
Country: Cayman Islands
Website: www.easismarthomes.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EASI, the Dark Horse of the Smart Home Industry, Introduces Neom Futuristic City to Transform Middle East Industry

EDsmart Releases 2024’s Most Affordable Online RN to BSN Programs Ranking

“EDsmart.org, a nationally recognized publisher of college resources and rankings, has released the 2024 edition of the Most Affordable Online RN to BSN Programs.”

EDsmart’s ranking of the Most Affordable Online RN to BSN Programs is the most comprehensive and well-rounded to date. The ranking includes only fully accredited schools. Rankings are based on affordability according to data gathered from the U.S. Department of Education.

“As online degrees become more prevalent, it is important to recognize the colleges and universities that go above and beyond,” said Tyson Stevens, managing editor of EDsmart. “Our goal is to highlight these schools and their commitment to higher education.”

“The Most Affordable Online RN to BSN Programs ranking allows students to compare accredited programs and find those that best fit their education interests and career goals,” said EDsmart’s spokesperson. “Beyond providing affordable education, a college is not successful if it does not graduate its students, which is why EDsmart rankings place a high value on outcomes, including graduation and retention rates, and post-graduation earnings.”

The EDsmart 2024 ranking for the Most Affordable Online RN to BSN Programs ranks Texas A & M International University #1 as the best college offering affordable Online RN to BSN degrees with Florida International University and Fayetteville State University following.

The complete rankings are as follows:

Texas A & M International University

Florida International University

Fayetteville State University

Farmingdale State College

Oklahoma Panhandle State University

Florida Atlantic University

The University of Texas Permian Basin

University of Central Florida

California State University-East Bay

New Mexico Highlands University

University of Utah

Appalachian State University

Southern Illinois University-Edwardsville

North Carolina Central University

Westfield State University

University response to EDsmart rankings has been very positive. Sharing the rankings on their websites and via social media has helped schools attract new students and excite existing students and alumni.

The rankings and data were produced for EDsmart, a leading higher education research organization. All evaluated data was gathered from IPEDs, the U.S. Department of Higher Education, school websites, and other reputable sources.

The rankings have been published at

Most Affordable Online RN to BSN Programs 2024

About EDsmart

EDsmart reviews publicly available data to produce independent ranking assessments of various educational programs, in addition to student guides and resources. The site is regularly updated by a committed team of writers and researchers, who produce college rankings and resources that will help prospective and current college students get into, pay for, and thrive at the college of their choice.

Media Contact

Company Name: EDsmart

Contact Person: Tyson Stevens

Phone: (707) 595-0736

City: Draper, UT

Email: tstevens@edsmart.org

https://www.edsmart.org

Media Contact
Company Name: EDsmart
Contact Person: Tyson Stevens
Email: Send Email
Phone: (707) 595-0736
City: Draper
State: UT
Country: United States
Website: https://www.edsmart.org/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EDsmart Releases 2024\’s Most Affordable Online RN to BSN Programs Ranking

EDsmart Releases 2024’s Best Online Colleges in North Carolina Ranking

EDsmart.org, a nationally recognized publisher of college resources and rankings, has released the 2024 edition of the Best Online Colleges in North Carolina.

EDsmart’s ranking of the Best Online Colleges in North Carolina is the most comprehensive and well-rounded to date. The ranking includes only fully accredited schools. Rankings are based on affordability, salary after attending, student satisfaction, and student outcome, according to data gathered from the U.S. Department of Education.

“The Best Online Colleges in North Carolina ranking allows students to compare accredited programs and find those that best fit their education interests and career goals,” said EDsmart’s spokesperson. “Beyond providing affordable education, a college is not successful if it does not graduate its students, which is why EDsmart rankings place a high value on outcomes, including graduation and retention rates, and post-graduation earnings.”

The EDsmart 2024 ranking for the Best Online College’s in North Carolina ranks North Carolina State University at Raleigh #1 as the best college offering online degrees in North Carolina with Appalachian State University and University of North Carolina at Charlotte following.

The complete rankings are as follows:

North Carolina State University at Raleigh

Appalachian State University

University of North Carolina at Charlotte

East Carolina University

University of North Carolina Wilmington

University of North Carolina at Greensboro

Western Carolina University

North Carolina A&T State University

Fayetteville State University

Gardner-Webb University

The rankings have been published at

Accredited Online Colleges in North Carolina 2024

About EDsmart

Media Contact

Company Name: EDsmart

Contact Person: Tyson Stevens

Phone: (707) 595-0736

City: Draper, UT

Email: tstevens@edsmart.org

https://www.edsmart.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EDsmart Releases 2024\’s Best Online Colleges in North Carolina Ranking

The Life of Jesus: History’s Great Love Story by Rev Dr Geoffrey Waugh Offers Inspired Insight into the Radical Life and Love of Jesus

For centuries, Jesus Christ has transformed and continues to transform societies, impacting the lives of billions of people around the world. In The Life of Jesus: History’s Great Love Story, author Geoffrey Waugh offers fresh insight into the radical life and love of Jesus.

Rev Dr Geoffrey Waugh is the founding editor of the Renewal Journal (renewaljournal.com) and the author of many books on ministry and mission including The Life of Jesus, Flashpoints of Revival, Living in the Spirit, God’s Surprises, Journey into Ministry and Mission, and more.

After completing theological college, Geoff taught on renewal and revival at Bible College, Trinity Theological College, and Christian Heritage College. He has enjoyed cross-cultural mission and taught on revival to church leaders in Africa, Nepal, India, Sri Lanka, Myanmar, Thailand, the Philippines, China, and the South Pacific nations of Papua New Guinea, the Solomon Islands, Vanuatu, and Fiji. He has also led many teams on service and mission in Europe, Africa, Asia, and the South Pacific.

This one-on-one interview shares Geoffrey Waugh’s background and experience in writing The Life of Jesus: History’s Great Love Story.

Tell us about The Life of Jesus: History’s Great Love Story.

The Life of Jesus provides a brief overview of history’s great love story.

It gives a summary of the birth and boyhood of Jesus and describes his ministry through three Passover Festivals.

It includes a detailed chronology of Jesus’ life and ministry, and examines why such a popular, loving, and compassionate young leader would encounter such intense hostility and opposition, leading to his crucifixion.

Offering fresh insights, The Life of Jesus points you to the great good news of who Jesus is and what he did.

What inspired you to write The Life of Jesus: History’s Great Love Story?

The life of Jesus is a vast topic, with millions of books written about it. I wanted to write a summary overview that people of all ages could read and understand.

In the book, I explore why such a young, radical leader who loved all people of all races was executed, and why we date our calendars and diaries from the time of his birth. I hope my contribution provides a helpful overview.

How did your background and experience influence your writing?

I have always believed in Jesus. Even as a small boy, I loved to hear and read stories about him because he was so unique and different. He always did what was good. He healed the sick, fed the hungry, set people free from addictions and evil, performed miracles, and even raised dead people. Huge crowds of people followed him and wanted him to be their king. Now, billions of people follow him, captivated and transformed by his love.

Through my experience teaching about Jesus in colleges in five countries, and speaking about Him through invitations from community groups in twenty countries, my passion and dedication has grown. Through the book, I offer fresh insights into his life and love.

What is one message you would like readers to remember?

Jesus’ unique and wonderful life, his brutal death for us, and his powerful resurrection, all reveal his and God’s eternal love for us all. That love, powerfully shown on the cross, has transformed billions of lives, restoring believers to an intimate and eternal relationship with God and with others.

Purchasing the Book

The Life of Jesus: History’s Great Love Story has received positive reviews from well-known literary organizations, experts and reviewers around the world. Rev Dr Tony Cupit, Former Director of the Baptist World Alliance writes, “Geoff has used Scripture as his main source and has been faithful to both the divinity and humanity of Jesus as expressed in the Gospels. His use of chronology for headings and the many subheadings makes the book simpler to absorb, even for an enquirer or new believer…I warmly commend this book.” In addition, Rev Dr John Olley writes, “A most helpful telling of the life of Jesus…anyone using this book will be enriched.”

Powerful and informative, The Life of Jesus: History’s Great Love Story, is available for sale on Amazon, Barnes & Noble, Kobo, Google Play, and other online bookstores. Readers who are looking for a deeper understanding of the life and love of Jesus are encouraged to purchase their copy today: https://www.amazon.com/Life-Jesus-Historys-Great-Story/dp/1664268154

Connect with Geoffrey Waugh

https://renewaljournal.com/2022/05/08/the-life-of-jesus/

https://www.facebook.com/HistorysGreatLoveStory

https://www.westbowpress.com/en/bookstore/bookdetails/841002-the-life-of-jesus

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Life of Jesus: History\’s Great Love Story by Rev Dr Geoffrey Waugh Offers Inspired Insight into the Radical Life and Love of Jesus

Transforming Perception, Elevating Care – Dr. Jaqlyn’s Tinaro Redefines Online Presence for a Healthier Tomorrow.

Dr. Jaqlyn’s Tinaro, a distinguished healthcare professional, proudly announces the launch of its revamped brand identity and website. This strategic move comes as part of a proactive approach to counter negative online sentiments and enhance the overall online presence.

Revolutionizing Online Presence

In an era where digital reputation is paramount, Dr. Jaqlyn’s Tinaro recognizes the importance of a positive and influential online image. The newly launched website, coupled with a revamped brand identity, is designed to address and counteract any negative reviews or information present on search engine result pages (SERPs).

Navigating Reputation Management Challenges

Dr. Jaqlyn’s Tinaro has taken a proactive stance in managing its online reputation. By investing in a comprehensive branding strategy and an upgraded website, the healthcare professional aims to present an accurate and positive representation to online audiences. The website serves as a hub for accurate and up-to-date information about Dr. Jaqlyn’s Tinaro’s values, and commitment to educating the public in regards to naturopathy and functional medicine. patient care.

Key Features of the Redesigned Website:

The website is designed with user experience in mind, offering a streamlined and user-friendly interface. Visitors can easily navigate through the site to find relevant information about Dr. Jaqlyn’s Tinaro’s expertise and products.

The site provides comprehensive details about education on naturopathy, spirituality and animal welfare.

Dr. Jaqlyn’s Tinaro recognizes the importance of education and transparency. The website features a blog and resources section to share valuable insights, tips, and industry updates, reinforcing the healthcare professional’s commitment to patient education.

To encourage communication and engagement, the website incorporates interactive contact options, making it easy for visitors to connect with Dr. Jaqlyn’s Tinaro for inquiries, or feedback.

Navigating Negative SERP Rankings

Acknowledging the challenges posed by negative search engine results, Dr. Jaqlyn’s Tinaro has implemented a targeted strategy to enhance its online reputation. The newly launched website is optimized to counteract negative information and present a more accurate and positive portrayal of Dr. Jaqlyn’s Tinaro’s professional achievements and commitment to education on Naturopathy and functional medicine.

Dr. Jaqlyn’s Tinaro on the Rebranding Effort

“Recognizing the significance of our online presence, we have undertaken this strategic rebranding initiative to ensure that our digital identity accurately reflects our values and commitment to healthcare excellence. Our revamped website not only provides a user-friendly experience but also serves as a tool to counteract any misleading information online,” says one of the clients’, the spokesperson for Dr. Jaqlyn’s Tinaro.

About Dr. Jaqlyn’s Tinaro

Dr. Jaqlyn’s Tinaro is a reputable Naturopath dedicated to providing high-quality education and insight on functional medicine, spirituality and holistic animal care. Dr. Jaqlyn’s Tinaro has taken proactive steps to address any challenges posed by negative online sentiments. Driven by a dedication to counteract negative sentiments on SERPs, Dr. Jaqlyn’s Tinaro strives to provide accurate information and foster trust. The newly launched website, https://www.drjaqlyn.com, reflects the commitment to transparency and education.

Media Contact
Company Name: Dr. Jaqlyn’s Tinaro
Contact Person: Media Relation
Email: Send Email
Country: United States
Website: https://www.drjaqlyn.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transforming Perception, Elevating Care – Dr. Jaqlyn\’s Tinaro Redefines Online Presence for a Healthier Tomorrow.

Make the Most of Winter Vacation with Colorado Resort Transportation by Epic Limo Services Inc.

To make the most of a trip, it’s essential to have reliable and convenient transportation. That’s where Epic Limo Services Inc comes in.

Winter vacation in Colorado is a magical time filled with snowy mountains, cozy cabins, and thrilling outdoor activities. To make the most of a trip, it’s essential to have reliable and convenient transportation. That’s where Epic Limo Services Inc comes in.

Epic Limo Services Inc offers top-notch transportation services specifically tailored to Colorado resorts. Whether you’re staying in Aspen, Vail, Breckenridge, or any other popular destination, their experienced drivers will ensure you reach your resort safely and on time.

Here’s how Epic Limo Services Inc can enhance your winter vacation:

1. Comfortable and Luxurious Vehicles: Traveling in style is always a plus, and Epic Limo Services Inc delivers just that. Their fleet consists of luxurious vehicles that are well-maintained and equipped with modern amenities, such as leather seats, climate control, and entertainment systems. Sit back, relax, and enjoy a comfortable ride to the resort.

2. Experienced and Professional Drivers: The drivers at Epic Limo Services Inc are not only experienced but also knowledgeable about the best routes to your destination. They are familiar with the road conditions during winter and know how to navigate through snow-covered mountain roads safely. You can trust them to provide a smooth and stress-free journey.

3. Safety First: Safety is a top priority for Epic Limo Services Inc. Their vehicles are equipped with advanced safety features, including anti-lock brakes and traction control, to ensure a secure ride. Additionally, their drivers undergo thorough background checks and regular training to guarantee your safety throughout the journey.

4. Convenience and Flexibility: Epic Limo Services Inc understands that vacation schedules can change, especially during the winter season when weather conditions can be unpredictable. That’s why they offer flexible transportation options. Whether you need a one-way trip, round-trip, or multiple stops along the way, they can accommodate your needs and adjust the schedule accordingly.

5. Local Expertise: Colorado is known for its stunning ski resorts, but there’s so much more to explore. Epic Limo Services Inc’s drivers have extensive knowledge of the area and can provide valuable recommendations on nearby attractions, restaurants, and activities. They can help you make the most of your vacation by suggesting hidden gems and local favorites.

Don’t let transportation woes dampen a winter vacation in Colorado. Choose Epic Limo Services Inc for reliable, comfortable, and convenient resort transportation. With their expertise and dedication to customer satisfaction, they will ensure that the trip is nothing short of epic.

Media Contact
Company Name: Epic Limo Services Inc.
Email: Send Email
Phone: (970) 390-0883
Address:1300 N Frontage Rd W #6135
City: Vail
State: CO
Country: United States
Website: https://epiclimovail.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Make the Most of Winter Vacation with Colorado Resort Transportation by Epic Limo Services Inc.

Cyclin-Dependent Kinase Inhibitor Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cyclin-Dependent Kinase Inhibitor pipeline constitutes 45+ key companies continuously working towards developing 52+ Cyclin-Dependent Kinase Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cyclin-Dependent Kinase Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cyclin-Dependent Kinase Inhibitor Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cyclin-Dependent Kinase Inhibitor Market.

Some of the key takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report:

Companies across the globe are diligently working toward developing novel Cyclin-Dependent Kinase Inhibitor treatment therapies with a considerable amount of success over the years.
Cyclin-Dependent Kinase Inhibitor companies working in the treatment market are Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others, are developing therapies for the Cyclin-Dependent Kinase Inhibitor treatment

Emerging Cyclin-Dependent Kinase Inhibitor therapies in the different phases of clinical trials are- SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others are expected to have a significant impact on the Cyclin-Dependent Kinase Inhibitor market in the coming years.
In April 2023, Insilico Medicine declared the successful identification of a powerful, specific, and orally absorbable small molecule CDK8 inhibitor for combating cancer. This breakthrough was achieved utilizing a structure-based generative chemistry method facilitated by the Chemistry42 multi-modal generative reinforcement learning platform. The research findings were published in the Journal of Medicinal Chemistry by the American Chemical Society, renowned for its contributions to medicinal chemistry.
In April 2023, Sumitomo Pharma Oncology, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to TP-1287, an experimental oral inhibitor targeting CDK9, for addressing Ewing sarcoma. TP-1287 serves as an investigative oral phosphate prodrug developed from the CDK9 inhibitor alvocidib.
In March 2023, Prelude Therapeutics Incorporated (Prelude) revealed a collaboration in clinical trials with BeiGene, aiming to explore their investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, for hematologic malignancies. According to the agreement, BeiGene will supply zanubrutinib to Prelude, granting Prelude complete global control over the operational, developmental, and commercial aspects associated with PRT2527.
In September 2022, Syros Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to SY-5609, intended for addressing pancreatic cancer. SY-5609 is an orally administered, highly selective, and potent inhibitor of cyclin-dependent kinase 7 (CDK7). Presently, it is under assessment in conjunction with chemotherapy as a potential treatment for patients confronting relapsed metastatic pancreatic cancer.
In September 2022, Qurient Co. Ltd. revealed its partnership with MSD (Merck & Co., Inc., Rahway, NJ., USA) through a clinical collaboration agreement concerning the examination of Q901, a specific CDK7 inhibitor, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab). As part of this agreement, Qurient will conduct a phase 1/2 study in the United States aimed at assessing the safety and effectiveness of Q901 along with KEYTRUDA for treating specific advanced solid tumors.
In March 2022, Kirilys Therapeutics, Inc., disclosed the closure of a seed funding round primarily overseen by Lightspeed Venture Partners. The company acquired the license for its primary compound, KRLS-017, from Ube Industries, Ltd., a leading Japanese chemical manufacturer. Additionally, Kirilys finalized a partnership pact with D2G Oncology, Inc., renowned for utilizing genetically defined animal tumor models to decipher connections between cancer genotypes and drug effectiveness. This funding round empowered Kirilys to complete all essential tasks until the IND filing of KRLS-017, including preliminary groundwork for the Phase 1 clinical development program.

Cyclin-Dependent Kinase Inhibitor Overview

The Cyclin-dependent kinase inhibitor protein, referred to as CKIs, CDIs, or CDKIs, acts as a suppressor of tumor growth by impeding the activity of cycling-dependent kinase (CDK) and Cyclin enzymes when the cell encounters unfavorable conditions. These proteins are involved in halting the cell cycle progression, particularly at the G1 phase, thereby preventing further advancement in unfavorable conditions.

Get a Free Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight

Emerging Cyclin-Dependent Kinase Inhibitor Drugs Under Different Phases of Clinical Development Include:

SY-5609: Syros Pharmaceutical
XL 102: Exelixis
PRT3645: Prelude Therapeutics
BLU 222: Blueprint Medicines
Enitociclib: Vincerx Pharma
SHR-6390: Jiangsu Hengrui Medicine Co.
Milciclib: Tiziana Life Sciences
XZP 3287: Xuanzhu Biopharmaceutical
Abemaciclib: Eli Lilly and Company
GB491 (lerociclib): Genor Pharma
Auceliciclib: Aucentra Therapeutics/University of South Australia
AU2-94: Aucentra Therapeutics

Cyclin-Dependent Kinase Inhibitor Route of Administration

Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Cyclin-Dependent Kinase Inhibitor Molecule Type

Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics Assessment

Cyclin-Dependent Kinase Inhibitor Assessment by Product Type
Cyclin-Dependent Kinase Inhibitor By Stage and Product Type
Cyclin-Dependent Kinase Inhibitor Assessment by Route of Administration
Cyclin-Dependent Kinase Inhibitor By Stage and Route of Administration
Cyclin-Dependent Kinase Inhibitor Assessment by Molecule Type
Cyclin-Dependent Kinase Inhibitor by Stage and Molecule Type

DelveInsight’s Cyclin-Dependent Kinase Inhibitor Report covers around 52+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Cyclin-Dependent Kinase Inhibitor product details are provided in the report. Download the Cyclin-Dependent Kinase Inhibitor pipeline report to learn more about the emerging Cyclin-Dependent Kinase Inhibitor therapies

Some of the key companies in the Cyclin-Dependent Kinase Inhibitor Therapeutics Market include:

Key companies developing therapies for Cyclin-Dependent Kinase Inhibitor are – MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, Exelixis, -Qurient Co. Ltd., OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others.

Cyclin-Dependent Kinase Inhibitor Pipeline Analysis:

The Cyclin-Dependent Kinase Inhibitor pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
Cyclin-Dependent Kinase Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor drugs and therapies

Cyclin-Dependent Kinase Inhibitor Pipeline Market Drivers

Rising prevalence of Cancer, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Cyclin-Dependent Kinase Inhibitor Market.

Cyclin-Dependent Kinase Inhibitor Pipeline Market Barriers

However, high cost associated with the treatment, side-effects associated with the Cyclin-Dependent Kinase Inhibitor immunotherapy and other factors are creating obstacles in the Cyclin-Dependent Kinase Inhibitor Market growth.

Scope of Cyclin-Dependent Kinase Inhibitor Pipeline Drug Insight

Coverage: Global
Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others
Key Cyclin-Dependent Kinase Inhibitor Therapies: SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others
Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment: Cyclin-Dependent Kinase Inhibitor current marketed and Cyclin-Dependent Kinase Inhibitor emerging therapies
Cyclin-Dependent Kinase Inhibitor Market Dynamics: Cyclin-Dependent Kinase Inhibitor market drivers and Cyclin-Dependent Kinase Inhibitor market barriers

Request for Sample PDF Report for Cyclin-Dependent Kinase Inhibitor Pipeline Assessment and clinical trials

Table of Contents

1. Cyclin-Dependent Kinase Inhibitor Report Introduction

2. Cyclin-Dependent Kinase Inhibitor Executive Summary

3. Cyclin-Dependent Kinase Inhibitor Overview

4. Cyclin-Dependent Kinase Inhibitor- Analytical Perspective In-depth Commercial Assessment

5. Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics

6. Cyclin-Dependent Kinase Inhibitor Late Stage Products (Phase II/III)

7. Cyclin-Dependent Kinase Inhibitor Mid Stage Products (Phase II)

8. Cyclin-Dependent Kinase Inhibitor Early Stage Products (Phase I)

9. Cyclin-Dependent Kinase Inhibitor Preclinical Stage Products

10. Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment

11. Cyclin-Dependent Kinase Inhibitor Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cyclin-Dependent Kinase Inhibitor Key Companies

14. Cyclin-Dependent Kinase Inhibitor Key Products

15. Cyclin-Dependent Kinase Inhibitor Unmet Needs

16 . Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers

17. Cyclin-Dependent Kinase Inhibitor Future Perspectives and Conclusion

18. Cyclin-Dependent Kinase Inhibitor Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cyclin-Dependent Kinase Inhibitor Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer

Halmahera Resources Works on Building a Stronger Line of Security

“halmaheraresources.com”

Safety production is a major concern and the company is committed to increasing employees’ safety awareness

Halmahera Resources, ISIN: IDA003250200, a leading low-cost producer of nickel that generates sustainable prosperity for our employees, investors, and the communities in which it operates, is pleased to announce that the company engages in actions to support production safety, and pays close attention to study and training.

Numerous business KPIs (Key Performance Indicators) are significantly impacted by worker safety. In other words, safer workplaces benefit from fewer accidents, which reduces the cost of occupational health care, improves employee satisfaction and retention, reduces employee downtime, and reduces the need for retraining.

“Halmahera Resources has established well-organized workplace safety policies. We recognize that missing prioritizing workplace safety can have negative effects on employees’ health, safety, and wellness and that having a solid plan in place can help prevent these problems. We are continuously taking measures to make sure we offer our employees a safe workplace”, said Hashim T. Panigoro, Chairman and CEO at Halmahera Resources.

An important step followed by the company is the creation of safety policies and procedures after listing all potential workplace dangers. Employees can consult the safety guidelines at Halmahera Resources whenever they are concerned.

Halmahera Resources keeps working on creating a workplace that is focused on the employees, reinforcing a great employee experience, and promoting a culture of safety. In that instance, it is imperative that all of the staff members — including supervisors and leaders—are coordinated and on the same page. The company does not overlook the significance of open and transparent workplace communications in this situation.

Safety communications are now being implemented by Halmahera Resources as a fundamental corporate value. This emphasis on creating a workplace that prioritizes safety enhances both employee satisfaction and financial performance.

About Halmahera Resources

HalmaheraResources.com takes pride in being a leading low-cost producer of nickel that generates sustainable prosperity for our employees, investors, and the communities in which it operates. Its primary objective is producing high-grade nickel at its Halmahera Project in South Halmahera Regency, North Maluku Province, Indonesia. As a byproduct of nickel mining, the company also produces cobalt, rhodium, selenium, tellurium, sulphur, and other products. The Halmahera Resources’ core operations are prospecting, exploration, mining, concentration, and processing of minerals along with the production, marketing, and sales of non-ferrous metals. The company views a firm commitment to the principles of social and environmental responsibility as a prerequisite for its sustainable and effective development.

Media Contact
Company Name: Halmahera Resources
Contact Person: Peter Thohir
Email: Send Email
Address:Jl. Jend. Sudirman No.kav. 5 – 6, RT.10/RW.11, Karet Tengsin, Tanahabang
City: Kota Jakarta Pusat
State: Daerah Khusus Ibukota Jakarta
Country: Indonesia
Website: https://halmaheraresources.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Halmahera Resources Works on Building a Stronger Line of Security

“Errare Humanum Est” the new Celtic song by Andrea Seki and Kristen Nikolas

“Errare Humanum Est” (Atlanteans Resonances Records) is poised for release on December 21, 2023, coinciding with the winter solstice—a song celebrating the beauty of flaws and inviting souls to find solace in the timeless melodies woven by Andrea Seki and Kristen Nikolas.

In the heart of the Celtic realms, where melodies dance with the wind and stories are whispered by ancient stones, there exists a harmony born of souls intertwined. Andrea Seki, a harpist, composer, and author, traces his musical journey through the intricate tapestry of his experiences and collaborations that have shaped his ethereal compositions.

His odyssey began amidst the enchanting landscapes of Brittany, where the whispers of the harp led him to the National School of Brest, guided by the revered Breton bard Alan Stivell. Here, Andrea delved into the realms of Celtic and neo-Celtic harps, steeping himself in their evocative, legendary essence.

Under the tutelage of the bardic harpist Myrdhin, founder of the International Celtic Harp Encounters in Dinan, Andrea honed his craft. Over the years, he immersed himself in the musical traditions of Brittany and Ireland, exploring the Vedic music of northern India and delving into ancient and modern sounds, from folk rock to classical and the cutting-edge realms of electro and trance.

The fruits of his artistic labor are strewn across a discography that spans decades, each album a testament to his evolution as an artist. From the ethereal whispers of “Fairylands” to the enchanting melodies of “A Journey to the Other Land,” Andrea’s compositions echo with a profound connection to nature, history, and the mythical.

But his story intertwines with another luminary of the Celtic musical landscape—Kristen Nikolas. A singer, songwriter, and seeker of ancient Celtic wisdom, Kristen’s path converged with Andrea’s in 1996. United by their reverence for ancient Celtic civilizations and maritime lore, their collaboration bore fruit in the stirring strains of “Son Atlantel” and continued to flourish through the resonating notes of “Errare Humanum Est.”

Kristen’s lyrical prose weaves tales inspired by life’s tapestry, drawn from encounters and the essence of the human experience. He shares his poetic process, a communion with nature, where words dance freely guided by the rhythm of the earth and sky. His writings, timeless and metaphoric, echo sentiments of unity amidst diversity—a testament to the beauty of our differences.

Their latest endeavor, “Errare Humanum Est,” (Atlanteans Resonances Records) melds Andrea’s evocative harp compositions with Kristen’s poignant verses. This melodic narrative, a synthesis of their artistic spirits, speaks of the human condition—its faults, its journey, and its intrinsic connection to the universal essence.

In this musical alchemy, they’ve beckoned a troupe of talented musicians, forging a new musical venture known as “C’hez An Avel Project” or “The Breath of the Wind.” With each member a virtuoso in their own right, the ensemble embodies a fusion of Breton and Tuscia influences, adding a touch of southern Italian melodies and chants by Biagio Accardi to the symphony.

The journey of their collaboration transcends geographical boundaries, echoing the mysticism of ancient lands—the Bretagne embracing Andrea for almost three decades, echoing the sacredness of Tuscia, a cradle of Etruscan and maritime cultures.

Patrice Marzin, an esteemed figure in Breton and Celtic music, echoed the magic woven by Andrea and Kristen, their harmonies a testament to a profound musical and human connection.

Their composition, a fusion of ancient echoes and contemporary resonance, is an invocation—an invitation for humanity to embrace its fallibilities and reconnect with its universal spirit. It is a symphony that celebrates the beauty of imperfections, urging us to dance to the rhythm of our own existence.

As they unleash this latest opus into the world, Andrea Seki and Kristen Nikolas stand as custodians of a musical heritage, weaving melodies that transcend time, beckoning souls to find solace and illumination in the symphony of life.

Errare Humanum Est (Atlanteans Resonances Records) will be released on Spotify and all digital streaming music providers around the world on December 21, 2023, the day of the winter solstice.

Credits:

Original music composed by Kristen Nikolas and Andrea Seki

Lyrics by Kristen Nikolas

Andrea Seki: Neo-Celtic harp, loops, fx, moog-bass, and backing vocals.

Kristen Nikolas: Singer and vocals

Konogan An Habask: Biniou, bombarde, uilian pipe, Low-istle

Daniele Sechi: Drums

Didier Dreo: Electric guitars Guest

Massimiliano Gallo: Viola Guest

Federica Faith: Choirs Guest

Alauna: Choirs – Expression vocal fx Guest

Biagio Accardi: Narrated voice Guest

Maxime Bourdon: Harmonica

Franky Cosentino: Sound recording and editing

Patrice Marzin @ Seniprod Kemper Studio – Mixing and mastering

Fabrizio Mancini: Artwork cover

Artistic director: Andrea Seki

Management/promotion/communication: Karine Hermen

Record Label: Atlanteans Resonances Records

Music publisher: Magic&Unique Music Publishing

Distribution: Magic&Unique Group LTD

Media Contact
Company Name: MAGIC&UNIQUE GROUP
Contact Person: JP DEVERA
Email: Send Email
Phone: +1 424 777 2283
City: LOS ANGELES
Country: United States
Website: www.magicandunique.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: \”Errare Humanum Est\” the new Celtic song by Andrea Seki and Kristen Nikolas